The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Half Sinemet CR 25mg/100mg Prolonged-Release Tablets

25 mg/100 milligram(s) Prolonged-release tablet

Merck Sharp & Dohme Ireland (Human Health) LimitedPA1286/009/001

Main Information

Trade NameHalf Sinemet CR 25mg/100mg Prolonged-Release Tablets
Active SubstancesCarbidopa
Strength25 mg/100 milligram(s)
Dosage FormProlonged-release tablet
Licence HolderMerck Sharp & Dohme Ireland (Human Health) Limited
Licence NumberPA1286/009/001

Group Information

ATC CodeN04BA Dopa and dopa derivatives
N04BA02 levodopa and decarboxylase inhibitor


Licence Issued22/02/1993
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back